1Hollstein M,Sidransky D,Vogelstein B,et al.p53 mutations in human cancers[J].Science,1991,253(5015):49-53.
2Vogelstein B,Lane D,Levine AJ.Surfing the p53 network[J].Nature,2000,408(6810):307-310.
3vanTuinen P,Ledbetter DH.Construction and utilization of a detailed somatic cell hybrid mapping panel for human chromosome 17:localization of an anonymous clone to the critical region of Miller-Dieker syndrome,deletion 17p13[J].Cytogene t Cell Genet,1987,46:708-709.
4Ziemer MA,Mason A,Carlson DM.Cellfree translations of proline-rich protein mRNAs[J].J Biol Chem,1982,257(18):11176-11180.
5Venot C,Maratrat M,Dureuil C,et al.The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression[J].EMBO J,1998,17(16):4668-4679.
6Harms KL,Chen X.The C terminus of p53 family proteins is a cell fate determinant[J].Mol Cell Bio1,2005,25(5):2014-2030.
7Storey A,Thomas M,Kalita A,et al.Role of a p53 polymorphism in the development of human papillomavirusassociated cancer[J].Nature,1998,393(6682):229-234.
8Jones SN,Roe AE,Donehower LA,et al.Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53[J].Nature,1995,378(6553):206-208.
9Montes de Oca Luna R,Wagner DS,Lozano G.Rescue of early embryonic lethality in Mdm2-deficient mice by deletion of p53[J].Nature,1995,378(6553):203-206.
10Murray-Zmijewski F,Slee EA,Lu X.A complex barcode underlies the heterogeneous response of p53 to stress[J].Nat Rev Mol Cell Biol,2008,9(9):702-712.
2[1]Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells:Role of reactive oxygen species[J] .Proc Natl Acad Sci USA, 1998,95:8103-8107.
3[2]Hollstein M,Sidransky D, Vogelstoin B, et al.p53 mutations in human cancers[J]. Science, 1991,253:49-53.
4[6]Shibate A, Ohneseit PF, Tsai YC, et al. Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan[J].Carcinogenesis, 1994,15: 1085-4-1087.
5[7]Hsu CH, Yang SA,Wang JY,et al. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan [J]. Br J Cancer, 1999,80:1080-1086.
8Chanda S,Dasgupta UB,Guhamazumder D,et al.DNA hypermethylation of promoter of gene p53 and p16 in arsenicexposed people with and without malignancy.Toxicol Sci,2006,89:431-437.
9Gomes NP,Espinosa JM.Differential regulation of p53 target genes:it' s (core promoter) elementary.Genes Dev,2010,24:111-114.
10Zhaag A,Feng H,Yang G,et al.Unventilated indoor coal-fired stoves in Guizhou province,China:cellular and genetic damage in villagers exposed to arsenic in food and air.Environ Health Perspect,2007,115:653-658.
1MeConnell TG, Murphy KM, Hafcz M, et al. Diagnosis and subclass- sification of hydatidiform moles using p57 immunohistochemistry and molecular genotyping: validation and prospective analysis in routine and consultation practice settings with development of an algorithmic approach [J]. Am J Surg Patho1,2009,33 (6) : 805 - 817.
2Chew SH, Perlman EJ, Williams R, et al. Morphology and DNA content analysis in the evaluation of first trimester placentas for partial hydatidiform mole ( PHM ) [J]. Hum Pathol, 2000, 31 (8) :914 -924.
3Kale A, Soylemez F, Ensari A. Expressions of proliferation markers ( Ki-67, proliferating cell nuclear antigen, and si|verstaining nucleolar organizer regions ) and of p53 tumor protein in gestational trophoblastic disease [ J ]. Am J Obstet Gynecol,2001,184(4) :567 - 574.
4Erfanian M, Sharifi N, Omidi AA. P63 and Ki-67 expression in trophoblastie disease and spontaneous abortion[ J]. JRMS, 2009, 14(6) : 375 -384.
5Chen Y, Shen D, Gu Y, et al. The diagnostic value of Ki-67, P53 and P63 in distinguishing partial Hydatidiform mole from hydropic abortion [J]. Wien Klin Wochenschr. 2012,124 (5 - 6) :184 - 187.
6Fisher RA, Nucci MR, Thaker HM, et al. Complete hydatidiform mole retaining a chromosome 11 of maternal origin: molecular genetic analysis of a case [ J ]. Mod Patrol, 2004,17 (9) :1155 - 1160.
7Al-Bozom IA. p53 and Bcl-2 oncoprotein expression in placentas with hydropic changes and partial and complete moles [ J ]. APMIS ,2000 , 108 ( 11 ) : 756 - 760.
8Rath G, Soni S, Prasad CP, et al. Bel-2 and p53 expressions in Indian women with complete hydatidiform mole [ J ]. Singapore Med J, 2011,52(7) : 502 -507.
9Yazaki-Sun S, Daher S, de Souza Ishigai MM. Correlation of c- erbB-2 oncogene and p53 tumor suppressor gene with malignant transformation of hydatidiform mole [ J ]. J Obstet Gynaecol Res, 2006,32(3) : 265 - 272.
10Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth [J]. Gene,2001,277(1 -2):15 -30.
